Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)

P. Wijermans(Haga Hospital), Michael Lübbert(University of Freiburg), Björn Rüter(University of Freiburg), Maria R. Baer(University of Maryland, Baltimore), H. I. Saba(Moffitt Cancer Center), James L. Slack(Memorial Sloan Kettering Cancer Center)
Leukemia Research
September 19, 2007
10.1016/j.leukres.2007.08.004
Cited by 125

Related Papers

Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
|Journal of Clinical Oncology|2010|764